42 related articles for article (PubMed ID: 38486481)
1. A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Scalise CB; Kincaid K; Thigpen H; Moore J; Dover B; Norian L; Meza-Perez S; Randall T; Birrer M; Odunsi K; Arend RC
Gynecol Oncol; 2024 Jun; 185():83-94. PubMed ID: 38377762
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations.
Priyankha S; Prakash M
J Biomol Struct Dyn; 2024 Jun; ():1-15. PubMed ID: 38887043
[TBL] [Abstract][Full Text] [Related]
3. Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators.
Jadav R; Weiland F; Noordermeer SM; Carroll T; Gao Y; Wang J; Zhou H; Lamoliatte F; Toth R; Macartney T; Brown F; Hastie CJ; Alabert C; van Attikum H; Zenke F; Masson JY; Rouse J
Mol Cell Proteomics; 2024 Jun; ():100802. PubMed ID: 38880245
[TBL] [Abstract][Full Text] [Related]
4. AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian Cancer.
Huang TT; Chiang CY; Nair JR; Wilson KM; Cheng K; Lee JM
Cancer Res; 2024 Mar; 84(6):887-904. PubMed ID: 38241710
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
6. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
7. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
8. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
9. AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract][Full Text] [Related]
10. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
11. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
Hinchcliff E; Chelariu-Raicu A; Westin SN
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
[TBL] [Abstract][Full Text] [Related]
12. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]